Functional estrogen receptor signal transduction pathway activity and antihormonal therapy response in low‐grade ovarian carcinoma
Background Advanced low‐grade ovarian carcinoma (LGOC) is difficult to treat. In several studies, high estrogen receptor (ER) protein expression was observed in patients with LGOC, which suggests that antihormonal therapy (AHT) is a treatment option. However, only a subgroup of patients respond to A...
Gespeichert in:
| Veröffentlicht in: | Cancer 2023-05, Vol.129 (9), p.1361-1371 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1371 |
|---|---|
| container_issue | 9 |
| container_start_page | 1361 |
| container_title | Cancer |
| container_volume | 129 |
| creator | Hendrikse, Cynthia S. E. Ploeg, Phyllis Kruis, Nienke M. A. Wilting, Jody H. C. Oosterkamp, Floor Theelen, Pauline M. M. Lok, Christianne A. R. Hullu, Joanne A. Smedts, Huberdina P. M. Vos, M. Caroline Pijlman, Brenda M. Kooreman, Loes F. S. Bulten, Johan Lentjes‐Beer, Marjolein H. F. M. Bosch, Steven L. Stolpe, Anja Lambrechts, Sandrina Bekkers, Ruud L. M. Piek, Jurgen M. J. |
| description | Background
Advanced low‐grade ovarian carcinoma (LGOC) is difficult to treat. In several studies, high estrogen receptor (ER) protein expression was observed in patients with LGOC, which suggests that antihormonal therapy (AHT) is a treatment option. However, only a subgroup of patients respond to AHT, and this response cannot be adequately predicted by currently used immunohistochemistry (IHC). A possible explanation is that IHC only takes the ligand, but not the activity, of the whole signal transduction pathway (STP) into account. Therefore, in this study, the authors assessed whether functional STP activity can be an alternative tool to predict response to AHT in LGOC.
Methods
Tumor tissue samples were obtained from patients with primary or recurrent LGOC who subsequently received AHT. Histoscores of ER and progesterone receptor (PR) were determined. In addition, STP activity of the ER STP and of six other STPs known to play a role in ovarian cancer was assessed and compared with the STP activity of healthy postmenopausal fallopian tube epithelium.
Results
Patients who had normal ER STP activity had a progression‐free survival (PFS) of 16.1 months. This was significantly shorter in patients who had low and very high ER STP activity, with a median PFS of 6.0 and 2.1 months, respectively (p |
| doi_str_mv | 10.1002/cncr.34661 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2783497686</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2783497686</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3931-b7624b8d35bf32b3959149ecbb868f6acc8db6d41709870b3464ef06b0c8ec093</originalsourceid><addsrcrecordid>eNp9kc9q3DAQh0VoSTZpLnmAIuilBJxIlqw_x7A0bSG0EBLozUiyvKtgS65kZ9lbD32APGOfpPJukkMPPYjRMB8fzPwAOMPoAiNUXhpv4gWhjOEDsMBI8gJhWr4BC4SQKCpKfhyB45QecsvLihyCI8IE4xVnC_D7evJmdMGrDto0xrCyHkZr7DCGCJNbzYMxKp-aacfBQY3rjdpCldtHN-aPb_Ib3TrEfucZ1zaqYZs1aQg-Weg87MLmz6-nVVSNheFRRac8NCoa50Ov3oG3reqSPX2uJ-D--tPd8ktx8_3z1-XVTWGIJLjQnJVUi4ZUuiWlJrKSmEprtBZMtEwZIxrNGoo5koIjnU9CbYuYRkZYgyQ5AR_33iGGn1Net-5dMrbrlLdhSnXJBaGS5-Nk9MM_6EOYYt5upiSngiE8U-d7ysSQUrRtPUTXq7itMarnbOo5m3qXTYbfPysn3dvmFX0JIwN4D2xcZ7f_UdXLb8vbvfQvDrCdrg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2797486016</pqid></control><display><type>article</type><title>Functional estrogen receptor signal transduction pathway activity and antihormonal therapy response in low‐grade ovarian carcinoma</title><source>Wiley Free Content</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Hendrikse, Cynthia S. E. ; Ploeg, Phyllis ; Kruis, Nienke M. A. ; Wilting, Jody H. C. ; Oosterkamp, Floor ; Theelen, Pauline M. M. ; Lok, Christianne A. R. ; Hullu, Joanne A. ; Smedts, Huberdina P. M. ; Vos, M. Caroline ; Pijlman, Brenda M. ; Kooreman, Loes F. S. ; Bulten, Johan ; Lentjes‐Beer, Marjolein H. F. M. ; Bosch, Steven L. ; Stolpe, Anja ; Lambrechts, Sandrina ; Bekkers, Ruud L. M. ; Piek, Jurgen M. J.</creator><creatorcontrib>Hendrikse, Cynthia S. E. ; Ploeg, Phyllis ; Kruis, Nienke M. A. ; Wilting, Jody H. C. ; Oosterkamp, Floor ; Theelen, Pauline M. M. ; Lok, Christianne A. R. ; Hullu, Joanne A. ; Smedts, Huberdina P. M. ; Vos, M. Caroline ; Pijlman, Brenda M. ; Kooreman, Loes F. S. ; Bulten, Johan ; Lentjes‐Beer, Marjolein H. F. M. ; Bosch, Steven L. ; Stolpe, Anja ; Lambrechts, Sandrina ; Bekkers, Ruud L. M. ; Piek, Jurgen M. J.</creatorcontrib><description>Background
Advanced low‐grade ovarian carcinoma (LGOC) is difficult to treat. In several studies, high estrogen receptor (ER) protein expression was observed in patients with LGOC, which suggests that antihormonal therapy (AHT) is a treatment option. However, only a subgroup of patients respond to AHT, and this response cannot be adequately predicted by currently used immunohistochemistry (IHC). A possible explanation is that IHC only takes the ligand, but not the activity, of the whole signal transduction pathway (STP) into account. Therefore, in this study, the authors assessed whether functional STP activity can be an alternative tool to predict response to AHT in LGOC.
Methods
Tumor tissue samples were obtained from patients with primary or recurrent LGOC who subsequently received AHT. Histoscores of ER and progesterone receptor (PR) were determined. In addition, STP activity of the ER STP and of six other STPs known to play a role in ovarian cancer was assessed and compared with the STP activity of healthy postmenopausal fallopian tube epithelium.
Results
Patients who had normal ER STP activity had a progression‐free survival (PFS) of 16.1 months. This was significantly shorter in patients who had low and very high ER STP activity, with a median PFS of 6.0 and 2.1 months, respectively (p < .001). Unlike ER histoscores, PR histoscores were strongly correlated to the ER STP activity and thus to PFS.
Conclusions
Aberrant low and very high functional ER STP activity and low PR histoscores in patients with LGOC indicate decreased response to AHT. ER IHC is not representative of functional ER STP activity and is not related to PFS.
Patients who have low‐grade ovarian carcinoma with a functionally low or high active estrogen receptor signaling pathway have a decreased response to antihormonal therapy. Estrogen receptor immunohistochemistry does not have predictive value for antihormonal therapy response and is not representative of functional estrogen receptor signaling.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.34661</identifier><identifier>PMID: 36867576</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>antihormonal therapy ; Biomarkers, Tumor - metabolism ; Cancer ; Carcinoma, Ovarian Epithelial - drug therapy ; Epithelium ; Estrogen receptors ; Estrogens ; Fallopian tube ; Female ; Humans ; Immunohistochemistry ; Neoplasm Recurrence, Local - drug therapy ; Oncology ; Ovarian cancer ; Ovarian carcinoma ; Ovarian Neoplasms ; Post-menopause ; Progesterone ; Receptors ; Receptors, Estrogen - metabolism ; Receptors, Progesterone - metabolism ; Signal Transduction ; signal transduction pathway ; Subgroups ; survival ; targeted therapy</subject><ispartof>Cancer, 2023-05, Vol.129 (9), p.1361-1371</ispartof><rights>2023 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.</rights><rights>2023. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3931-b7624b8d35bf32b3959149ecbb868f6acc8db6d41709870b3464ef06b0c8ec093</citedby><cites>FETCH-LOGICAL-c3931-b7624b8d35bf32b3959149ecbb868f6acc8db6d41709870b3464ef06b0c8ec093</cites><orcidid>0000-0001-8108-6659</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcncr.34661$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcncr.34661$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36867576$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hendrikse, Cynthia S. E.</creatorcontrib><creatorcontrib>Ploeg, Phyllis</creatorcontrib><creatorcontrib>Kruis, Nienke M. A.</creatorcontrib><creatorcontrib>Wilting, Jody H. C.</creatorcontrib><creatorcontrib>Oosterkamp, Floor</creatorcontrib><creatorcontrib>Theelen, Pauline M. M.</creatorcontrib><creatorcontrib>Lok, Christianne A. R.</creatorcontrib><creatorcontrib>Hullu, Joanne A.</creatorcontrib><creatorcontrib>Smedts, Huberdina P. M.</creatorcontrib><creatorcontrib>Vos, M. Caroline</creatorcontrib><creatorcontrib>Pijlman, Brenda M.</creatorcontrib><creatorcontrib>Kooreman, Loes F. S.</creatorcontrib><creatorcontrib>Bulten, Johan</creatorcontrib><creatorcontrib>Lentjes‐Beer, Marjolein H. F. M.</creatorcontrib><creatorcontrib>Bosch, Steven L.</creatorcontrib><creatorcontrib>Stolpe, Anja</creatorcontrib><creatorcontrib>Lambrechts, Sandrina</creatorcontrib><creatorcontrib>Bekkers, Ruud L. M.</creatorcontrib><creatorcontrib>Piek, Jurgen M. J.</creatorcontrib><title>Functional estrogen receptor signal transduction pathway activity and antihormonal therapy response in low‐grade ovarian carcinoma</title><title>Cancer</title><addtitle>Cancer</addtitle><description>Background
Advanced low‐grade ovarian carcinoma (LGOC) is difficult to treat. In several studies, high estrogen receptor (ER) protein expression was observed in patients with LGOC, which suggests that antihormonal therapy (AHT) is a treatment option. However, only a subgroup of patients respond to AHT, and this response cannot be adequately predicted by currently used immunohistochemistry (IHC). A possible explanation is that IHC only takes the ligand, but not the activity, of the whole signal transduction pathway (STP) into account. Therefore, in this study, the authors assessed whether functional STP activity can be an alternative tool to predict response to AHT in LGOC.
Methods
Tumor tissue samples were obtained from patients with primary or recurrent LGOC who subsequently received AHT. Histoscores of ER and progesterone receptor (PR) were determined. In addition, STP activity of the ER STP and of six other STPs known to play a role in ovarian cancer was assessed and compared with the STP activity of healthy postmenopausal fallopian tube epithelium.
Results
Patients who had normal ER STP activity had a progression‐free survival (PFS) of 16.1 months. This was significantly shorter in patients who had low and very high ER STP activity, with a median PFS of 6.0 and 2.1 months, respectively (p < .001). Unlike ER histoscores, PR histoscores were strongly correlated to the ER STP activity and thus to PFS.
Conclusions
Aberrant low and very high functional ER STP activity and low PR histoscores in patients with LGOC indicate decreased response to AHT. ER IHC is not representative of functional ER STP activity and is not related to PFS.
Patients who have low‐grade ovarian carcinoma with a functionally low or high active estrogen receptor signaling pathway have a decreased response to antihormonal therapy. Estrogen receptor immunohistochemistry does not have predictive value for antihormonal therapy response and is not representative of functional estrogen receptor signaling.</description><subject>antihormonal therapy</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Cancer</subject><subject>Carcinoma, Ovarian Epithelial - drug therapy</subject><subject>Epithelium</subject><subject>Estrogen receptors</subject><subject>Estrogens</subject><subject>Fallopian tube</subject><subject>Female</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Oncology</subject><subject>Ovarian cancer</subject><subject>Ovarian carcinoma</subject><subject>Ovarian Neoplasms</subject><subject>Post-menopause</subject><subject>Progesterone</subject><subject>Receptors</subject><subject>Receptors, Estrogen - metabolism</subject><subject>Receptors, Progesterone - metabolism</subject><subject>Signal Transduction</subject><subject>signal transduction pathway</subject><subject>Subgroups</subject><subject>survival</subject><subject>targeted therapy</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp9kc9q3DAQh0VoSTZpLnmAIuilBJxIlqw_x7A0bSG0EBLozUiyvKtgS65kZ9lbD32APGOfpPJukkMPPYjRMB8fzPwAOMPoAiNUXhpv4gWhjOEDsMBI8gJhWr4BC4SQKCpKfhyB45QecsvLihyCI8IE4xVnC_D7evJmdMGrDto0xrCyHkZr7DCGCJNbzYMxKp-aacfBQY3rjdpCldtHN-aPb_Ib3TrEfucZ1zaqYZs1aQg-Weg87MLmz6-nVVSNheFRRac8NCoa50Ov3oG3reqSPX2uJ-D--tPd8ktx8_3z1-XVTWGIJLjQnJVUi4ZUuiWlJrKSmEprtBZMtEwZIxrNGoo5koIjnU9CbYuYRkZYgyQ5AR_33iGGn1Net-5dMrbrlLdhSnXJBaGS5-Nk9MM_6EOYYt5upiSngiE8U-d7ysSQUrRtPUTXq7itMarnbOo5m3qXTYbfPysn3dvmFX0JIwN4D2xcZ7f_UdXLb8vbvfQvDrCdrg</recordid><startdate>20230501</startdate><enddate>20230501</enddate><creator>Hendrikse, Cynthia S. E.</creator><creator>Ploeg, Phyllis</creator><creator>Kruis, Nienke M. A.</creator><creator>Wilting, Jody H. C.</creator><creator>Oosterkamp, Floor</creator><creator>Theelen, Pauline M. M.</creator><creator>Lok, Christianne A. R.</creator><creator>Hullu, Joanne A.</creator><creator>Smedts, Huberdina P. M.</creator><creator>Vos, M. Caroline</creator><creator>Pijlman, Brenda M.</creator><creator>Kooreman, Loes F. S.</creator><creator>Bulten, Johan</creator><creator>Lentjes‐Beer, Marjolein H. F. M.</creator><creator>Bosch, Steven L.</creator><creator>Stolpe, Anja</creator><creator>Lambrechts, Sandrina</creator><creator>Bekkers, Ruud L. M.</creator><creator>Piek, Jurgen M. J.</creator><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8108-6659</orcidid></search><sort><creationdate>20230501</creationdate><title>Functional estrogen receptor signal transduction pathway activity and antihormonal therapy response in low‐grade ovarian carcinoma</title><author>Hendrikse, Cynthia S. E. ; Ploeg, Phyllis ; Kruis, Nienke M. A. ; Wilting, Jody H. C. ; Oosterkamp, Floor ; Theelen, Pauline M. M. ; Lok, Christianne A. R. ; Hullu, Joanne A. ; Smedts, Huberdina P. M. ; Vos, M. Caroline ; Pijlman, Brenda M. ; Kooreman, Loes F. S. ; Bulten, Johan ; Lentjes‐Beer, Marjolein H. F. M. ; Bosch, Steven L. ; Stolpe, Anja ; Lambrechts, Sandrina ; Bekkers, Ruud L. M. ; Piek, Jurgen M. J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3931-b7624b8d35bf32b3959149ecbb868f6acc8db6d41709870b3464ef06b0c8ec093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>antihormonal therapy</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Cancer</topic><topic>Carcinoma, Ovarian Epithelial - drug therapy</topic><topic>Epithelium</topic><topic>Estrogen receptors</topic><topic>Estrogens</topic><topic>Fallopian tube</topic><topic>Female</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Oncology</topic><topic>Ovarian cancer</topic><topic>Ovarian carcinoma</topic><topic>Ovarian Neoplasms</topic><topic>Post-menopause</topic><topic>Progesterone</topic><topic>Receptors</topic><topic>Receptors, Estrogen - metabolism</topic><topic>Receptors, Progesterone - metabolism</topic><topic>Signal Transduction</topic><topic>signal transduction pathway</topic><topic>Subgroups</topic><topic>survival</topic><topic>targeted therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hendrikse, Cynthia S. E.</creatorcontrib><creatorcontrib>Ploeg, Phyllis</creatorcontrib><creatorcontrib>Kruis, Nienke M. A.</creatorcontrib><creatorcontrib>Wilting, Jody H. C.</creatorcontrib><creatorcontrib>Oosterkamp, Floor</creatorcontrib><creatorcontrib>Theelen, Pauline M. M.</creatorcontrib><creatorcontrib>Lok, Christianne A. R.</creatorcontrib><creatorcontrib>Hullu, Joanne A.</creatorcontrib><creatorcontrib>Smedts, Huberdina P. M.</creatorcontrib><creatorcontrib>Vos, M. Caroline</creatorcontrib><creatorcontrib>Pijlman, Brenda M.</creatorcontrib><creatorcontrib>Kooreman, Loes F. S.</creatorcontrib><creatorcontrib>Bulten, Johan</creatorcontrib><creatorcontrib>Lentjes‐Beer, Marjolein H. F. M.</creatorcontrib><creatorcontrib>Bosch, Steven L.</creatorcontrib><creatorcontrib>Stolpe, Anja</creatorcontrib><creatorcontrib>Lambrechts, Sandrina</creatorcontrib><creatorcontrib>Bekkers, Ruud L. M.</creatorcontrib><creatorcontrib>Piek, Jurgen M. J.</creatorcontrib><collection>Wiley-Blackwell Open Access Titles</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hendrikse, Cynthia S. E.</au><au>Ploeg, Phyllis</au><au>Kruis, Nienke M. A.</au><au>Wilting, Jody H. C.</au><au>Oosterkamp, Floor</au><au>Theelen, Pauline M. M.</au><au>Lok, Christianne A. R.</au><au>Hullu, Joanne A.</au><au>Smedts, Huberdina P. M.</au><au>Vos, M. Caroline</au><au>Pijlman, Brenda M.</au><au>Kooreman, Loes F. S.</au><au>Bulten, Johan</au><au>Lentjes‐Beer, Marjolein H. F. M.</au><au>Bosch, Steven L.</au><au>Stolpe, Anja</au><au>Lambrechts, Sandrina</au><au>Bekkers, Ruud L. M.</au><au>Piek, Jurgen M. J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Functional estrogen receptor signal transduction pathway activity and antihormonal therapy response in low‐grade ovarian carcinoma</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2023-05-01</date><risdate>2023</risdate><volume>129</volume><issue>9</issue><spage>1361</spage><epage>1371</epage><pages>1361-1371</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><abstract>Background
Advanced low‐grade ovarian carcinoma (LGOC) is difficult to treat. In several studies, high estrogen receptor (ER) protein expression was observed in patients with LGOC, which suggests that antihormonal therapy (AHT) is a treatment option. However, only a subgroup of patients respond to AHT, and this response cannot be adequately predicted by currently used immunohistochemistry (IHC). A possible explanation is that IHC only takes the ligand, but not the activity, of the whole signal transduction pathway (STP) into account. Therefore, in this study, the authors assessed whether functional STP activity can be an alternative tool to predict response to AHT in LGOC.
Methods
Tumor tissue samples were obtained from patients with primary or recurrent LGOC who subsequently received AHT. Histoscores of ER and progesterone receptor (PR) were determined. In addition, STP activity of the ER STP and of six other STPs known to play a role in ovarian cancer was assessed and compared with the STP activity of healthy postmenopausal fallopian tube epithelium.
Results
Patients who had normal ER STP activity had a progression‐free survival (PFS) of 16.1 months. This was significantly shorter in patients who had low and very high ER STP activity, with a median PFS of 6.0 and 2.1 months, respectively (p < .001). Unlike ER histoscores, PR histoscores were strongly correlated to the ER STP activity and thus to PFS.
Conclusions
Aberrant low and very high functional ER STP activity and low PR histoscores in patients with LGOC indicate decreased response to AHT. ER IHC is not representative of functional ER STP activity and is not related to PFS.
Patients who have low‐grade ovarian carcinoma with a functionally low or high active estrogen receptor signaling pathway have a decreased response to antihormonal therapy. Estrogen receptor immunohistochemistry does not have predictive value for antihormonal therapy response and is not representative of functional estrogen receptor signaling.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>36867576</pmid><doi>10.1002/cncr.34661</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0001-8108-6659</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 2023-05, Vol.129 (9), p.1361-1371 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2783497686 |
| source | Wiley Free Content; MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | antihormonal therapy Biomarkers, Tumor - metabolism Cancer Carcinoma, Ovarian Epithelial - drug therapy Epithelium Estrogen receptors Estrogens Fallopian tube Female Humans Immunohistochemistry Neoplasm Recurrence, Local - drug therapy Oncology Ovarian cancer Ovarian carcinoma Ovarian Neoplasms Post-menopause Progesterone Receptors Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism Signal Transduction signal transduction pathway Subgroups survival targeted therapy |
| title | Functional estrogen receptor signal transduction pathway activity and antihormonal therapy response in low‐grade ovarian carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T18%3A00%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Functional%20estrogen%20receptor%20signal%20transduction%20pathway%20activity%20and%20antihormonal%20therapy%20response%20in%20low%E2%80%90grade%20ovarian%20carcinoma&rft.jtitle=Cancer&rft.au=Hendrikse,%20Cynthia%20S.%20E.&rft.date=2023-05-01&rft.volume=129&rft.issue=9&rft.spage=1361&rft.epage=1371&rft.pages=1361-1371&rft.issn=0008-543X&rft.eissn=1097-0142&rft_id=info:doi/10.1002/cncr.34661&rft_dat=%3Cproquest_cross%3E2783497686%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2797486016&rft_id=info:pmid/36867576&rfr_iscdi=true |